CREATE-1: A Study to Assess the Efficacy and Safety of AXS-02 in Patients With CRPS-1

PHASE3UnknownINTERVENTIONAL
Enrollment

190

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

January 31, 2019

Study Completion Date

January 31, 2019

Conditions
Complex Regional Pain SyndromeReflex Sympathetic Dystrophy
Interventions
DRUG

AXS-02 (oral zoledronate)

Once weekly for 6 weeks

DRUG

Placebo

Once weekly for 6 weeks

Trial Locations (44)

31558

St. Marys

32827

Orlando

Unknown

Tucson

Hot Springs

Encinitas

La Jolla

Los Angeles

Napa

Temecula

Denver

Clermont

Miami

Tampa

West Palm Beach

Canton

Marietta

Meridian

Chicago

Louisville

Albuquerque

New York

Winston-Salem

Oklahoma City

Portland

Dallas

San Antonio

Bellevue

Seattle

Madison

Broadmeadow

Hurstville

Noosa

Welland

Clayton

Nedlands

Sherbrooke

Warrington

Darlington

Lambeth

Liverpool

Norwich

Newcastle upon Tyne

Glasgow

London

Sponsors
All Listed Sponsors
lead

Axsome Therapeutics, Inc.

INDUSTRY